drugset
drugset / Trial / NCT04789096

Tucatinib Together With Pembrolizumab and Trastuzumab

NCT04789096 ↗

Phase 2 Terminated 31 enrolled Breast Cancer Trials, Australia and New Zealand
NaSingle-groupOpen-labelTreatment

Summary

Women or men with HER2-positive, metastatic breast cancer, who have progressed on previous treatment, will receive tucatinib in combination with pembrolizumab and trastuzumab (PD-L1 positive).

Timeline

Start
2023-03-07
Primary completion
2025-06-04
Completion
2025-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Subject Tucatinib Small molecule 300 mg Oral

Indications

HER2 positive breast carcinoma